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The importance of rare variants in complex disease
Genome-wide association scans have discovered common-
frequency  variants  that  play  a  role  in  complex  disease 
susceptibility. However, these variants account for only a 
small fraction of the genetic component of disease. Rare 
variants are hypothesized to have larger effect sizes and 
may help fill in some of this heritability gap. In recent 
studies,  rare  variants  have  been  shown  to  play  an 
important  role  in  complex  disease  etiology  [1,2]. 
Assessing the role of rare variants in complex diseases is 
becoming  increasingly  feasible  as  next-generation 
sequencing technologies allow the efficient genome-wide 
sequencing of many individuals.
Single-variant association tests have been successful in 
detecting disease-associated common variants, but such 
tests  have  been  shown  to  be  sensitive  to  both  allele 
frequency and effect size, so that they are underpowered 
in  analyzing  rare  variants  [3,4].  More  powerful 
approaches to rare variant analyses are locus-based tests 
that  collectively  test  all  of  the  rare  variants  within  a 
region,  which  may  be  a  gene  or  other  functional  unit, 
such as a regulatory region. Several statistical methods 
have been proposed for rare variant analyses (as reviewed 
by Asimit and Zeggini [5]), but many of them experience 
a  large  drop  in  power  when  both  protective  and  risk 
variants  are  present  in  a  genetic  region  of  interest. 
Indeed, over 20 different methods have been proposed in 
the last 2 to 3 years, each with distinct properties under 
different allelic architecture scenarios [5].
In a recent PLoS Genetics publication, Ionita-Laza et al. 
[6]  introduced  a  testing  approach,  referred  to  as  a 
replication-based  strategy  that  is  less  sensitive  to  the 
presence  of  both  risk  and  protective  variants  in  the 
region.  Here,  we  discuss  the  method  and  the  authors’ 
find  ings when comparing it with two existing rare variant 
analysis  methods  proposed  by  Li  and  Leal  [3]  and  by 
Browning and Browning [7]. We also discuss the state of 
the field of rare variant analysis in complex traits, and the 
likely clinical implications when the proposed methods 
start to be applied to real data to identify novel disease 
associations at a wider scale.
The replication-based strategy
The  method  of  Ionita-Laza  et  al.  [6]  is  based  on  a 
weighted-sum statistic that evaluates whether an accu-
mu  lation of rare variants occurs in a particular region at 
significantly  higher  frequencies  in  either  cases  or 
controls.  Two  one-sided  test  statistics  may  be  formed: 
one for testing higher frequencies in cases than controls 
(risk  variants)  and  one  for  the  converse  test  of  higher 
frequencies in controls than cases (protective variants). 
In  forming  each  one-sided  test  statistic,  the  observed 
variants in cases and controls are partitioned into distinct 
groups  according  to  the  counts  of  the  minor  allele  in 
cases, and the counts in controls.
The maximum of the two one-sided test statistics for 
testing  higher  frequencies  of  risk  variants  and  higher 
frequencies of protective variants can then be used to test 
whether the region has an accumulation of rare variants 
that  confer  either  protection  or  risk.  In  this  way  the 
strategy  avoids  combining  the  possibly  different  direc-
tional effects of the variants, which may dilute signals in 
cases where both risk and protective variants are present. 
As an alternative, Ionita-Laza et al. also investigated a 
combined test statistic that takes the sum of the two one-
sided test statistics, rather than their maximum [6].
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weighted-sum  statistic  from  the  replication-based 
strategy with the collapsing method of Li and Leal [3] 
and  the  weighted-sum  statistic  of  Browning  and 
Browning  [7],  the  maximum  test  statistic  consistently 
attained the highest power. When both protective and 
risk variants existed in the region, the collapsing method 
and weighted-sum statistic experienced large decreases 
in power from the ideal situation of only one direction of 
effect  for  causal  variants.  In  contrast,  the  approach 
proposed by Ionita-Laza et al. [6] was not as sensitive to 
the mixture of effect directions, although it still incurred 
moderate power losses.
Comparisons  between  the  two  versions  of  the 
replication-based strategy yielded interesting results. The 
maximum statistic showed a substantial power advantage 
over the combined statistic in a situation where only risk 
variants  were  present.  However,  as  the  number  of 
protective variants in the region increased, the power of 
the combined statistic was found to surpass that of the 
maximum  statistic.  Therefore,  both  replication-based 
strategy approaches can provide useful information, but 
the choice of which of the two to use depends on the 
underlying assumptions of the directions of effect for the 
causal variants in the region under investigation. This is a 
welcome step forward in the analysis of rare variants, but 
the  development  of  further  tests  for  simultaneously 
handling the effects of both protective and risk variants 
are required.
Disease-related implications of rare variant 
associations
Low frequency and rare variants conferring susceptibility 
to common complex disease may have larger effect sizes 
compared to the common-variant associations identified 
to  date.  Higher  penetrance  may  also  indicate  higher 
predictive  power  of  disease,  although  it  is  clear  that 
complex  traits  are  underpinned  by  combinations  of 
common and low frequency sequence variants, environ-
mental factors and their interactions. Rare variant asso-
cia  tions are also expected to more readily point to the 
causal locus or functional unit, potentially enhancing the 
translational potential of these findings.
Early  examples  of  low  frequency  and  rare  variant 
associations  with  complex  traits  have  arisen  from 
targeted resequencing experiments. For example, Cohen 
et  al.  [1]  detected  a  significant  over-representation  of 
non-synonymous variants in individuals with low plasma 
levels of high-density lipoprotein cholesterol compared 
with  those  with  high  plasma  levels  of  high-density 
lipoprotein  cholesterol.  More  recently,  Nejentsev  et  al. 
[2] followed a pooled resequencing approach to identify 
four rare variants within the IFIH1 (interferon induced 
with helicase C domain 1) gene that lower risk of type 1 
diabetes independently of each other. Rare variant minor 
alleles are expected to potentially confer increased risk or 
protection against disease.
Challenges for the detection of rare 
disease-associated variants
Many tests for associations with rare variants have been 
proposed, but the majority experience a massive loss in 
power when both protective and risk variants are present 
in the region under analysis. The novel testing strategy 
proposed by Ionita-Laza et al. [6] is more robust to the 
presence of both directions of effect for causal variants 
at  a  locus.  Their  replication-based  strategy  using  the 
maxi  mum statistic was demonstrated to outperform two 
existing methods for rare variant analyses, and did not 
lose  as  much  power  as  these  methods.  An  alternative 
form of their statistic, taking the sum rather than the 
maximum  of  two  one-sided  test  statistics,  showed  an 
even  larger  power  increase  when  both  protective  and 
risk  variants  were  present.  Both  the  maximum  and 
combined statistics represent an improvement over the 
existing methods they were compared against, but each 
performs  better  than  the  other  under  different 
assumptions. Indeed, it is widely accepted that different 
rare variant analysis methods perform optimally under 
different  allelic  heterogeneity  scenarios.  Due  to  the 
relative paucity of empirical data, there is no emerging 
consensus genetic architecture on which to focus further 
development. The advent of next-generation sequencing 
technologies  has  empowered  a  new  genre  of  genetic 
association studies that focus on low frequency and rare 
variants.  An  appropriate  analytical  toolbox  is  being 
developed, with probably more methods than empirical 
datasets available at this point in time. It is expected that 
rare variation will play a role in the etiology of common 
complex  diseases,  and  that  new  discoveries  will  shed 
further  light  into  the  biological  underpinnings  of 
pathological processes.
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